Exact Sciences Aims High with Robust Growth, Innovation, and a Clear Vision for 2025
Exact Sciences concluded 2024 with significant advancements in cancer diagnostics, impacting over 4.6 million patients through enhanced test results. Core revenue increased by 11%, aided by FDA approval and Medicare pricing for the Cologuard Plus colon cancer screening test. The company’s focus
